perioperative management of glp 1 agonists Holding GLP-1 Prior to Elective Procedures Anesthetic Considerations for Patients Taking
Description
X-FZ critically revised the manuscript
The approval was granted based on demonstrated improvements in MASH and fibrosis, and a confirmatory study is currently underway
If this is you after 2 months we would discontinue treatment and discuss another medication, such as TTA, Amlexanox or Semaglitude
10.3389/fphar.2020.589114
33 Overall, the consistent reduction in the risk of MACE and major adverse kidney events associated with GLP-1 RAs across patient subgroups underscores the potential of these agents in managing cardiorenal risk (Fig
Data shows the clinical value of this approach
